SCHEDULE: Theravance Biopharma Merger Complete, Shares Cancelled
Amendment to Schedule 13D
Weiss Asset Management LP and related entities report zero beneficial ownership of Theravance Biopharma, Inc. ordinary shares following the company's merger with Zymeworks Inc. and subsequent share cancellation.
Summary
- This filing is an amendment to a Schedule 13D, reporting changes related to Theravance Biopharma, Inc.
- The reporting persons, including Weiss Asset Management LP, BIP GP LLC, WAM GP LLC, and Andrew M. Weiss, now hold 0 shares, representing 0.0% of the outstanding shares.
- This change is due to the completion of a merger between Theravance Biopharma, Inc. and Zymeworks Inc.
- As a result of the merger, Theravance Biopharma, Inc. ordinary shares were cancelled on September 23, 2026.
- The percentages were calculated based on 51,918,754 shares outstanding as of July 31, 2026.
Sentiment
Score: 2
Explanation: StockSavvy.ai views this as a negative filing due to the confirmation of a merger completion and the subsequent cancellation of shares, indicating the end of Theravance Biopharma's independent existence and the reporting persons' zero beneficial ownership.
Negatives
- The reporting persons now hold zero shares in Theravance Biopharma, Inc.
- Theravance Biopharma, Inc. ordinary shares were cancelled on September 23, 2026, following its merger with Zymeworks Inc.
Future Outlook
The filing confirms the completion of the merger and the cancellation of shares, indicating the cessation of Theravance Biopharma, Inc. as an independent entity and the reporting persons' disclaimed beneficial ownership.
Industry Context
StockSavvy.ai notes that this filing marks the conclusion of Theravance Biopharma's independent corporate existence due to its merger with Zymeworks Inc., a common event in the biopharmaceutical industry driven by consolidation and strategic partnerships.
Stakeholder Impact
- Shareholders of Theravance Biopharma, Inc. have had their shares cancelled as part of the merger with Zymeworks Inc.
Next Steps
- The reporting persons will no longer hold beneficial ownership of Theravance Biopharma, Inc. shares.
- Theravance Biopharma, Inc. ordinary shares have been cancelled.
Key Dates
| Date | Description |
|---|---|
| 2026-07-31 | Date of Issuer's Form 8-K reporting outstanding shares. |
| 2026-09-18 | Date Theravance Biopharma, Inc. filed Form 8-K with outstanding share information. |
| 2026-09-23 | Date of event requiring filing of this statement; completion of merger and cancellation of shares. |
| 2026-09-25 | Date of signatures on the filing. |
Keywords
Merger, Share Cancellation, Beneficial Ownership, Schedule 13D, Zymeworks Inc.
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.